These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 34266882)

  • 1. Influence of DM-sensitivity on immunogenicity of MHC class II restricted antigens.
    Bernhardt AL; Zeun J; Marecek M; Reimann H; Kretschmann S; Bausenwein J; van der Meijden ED; Karg MM; Haug T; Meintker L; Lutzny-Geier G; Mackensen A; Kremer AN
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34266882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endogenous HLA class II epitopes that are immunogenic in vivo show distinct behavior toward HLA-DM and its natural inhibitor HLA-DO.
    Kremer AN; van der Meijden ED; Honders MW; Goeman JJ; Wiertz EJ; Falkenburg JH; Griffioen M
    Blood; 2012 Oct; 120(16):3246-55. PubMed ID: 22889757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human leukocyte antigen-DO regulates surface presentation of human leukocyte antigen class II-restricted antigens on B cell malignancies.
    Kremer AN; van der Meijden ED; Honders MW; Pont MJ; Goeman JJ; Falkenburg JH; Griffioen M
    Biol Blood Marrow Transplant; 2014 May; 20(5):742-7. PubMed ID: 24530695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of H2-O and HLA-DO in major histocompatibility complex class II-restricted antigen processing and presentation.
    Alfonso C; Liljedahl M; Winqvist O; Surh CD; Peterson PA; Fung-Leung WP; Karlsson L
    Immunol Rev; 1999 Dec; 172():255-66. PubMed ID: 10631951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Refining human T-cell immunotherapy of cytomegalovirus disease: a mouse model with 'humanized' antigen presentation as a new preclinical study tool.
    Lemmermann NA; Reddehase MJ
    Med Microbiol Immunol; 2016 Dec; 205(6):549-561. PubMed ID: 27539576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Minor histocompatibility antigen DBY elicits a coordinated B and T cell response after allogeneic stem cell transplantation.
    Zorn E; Miklos DB; Floyd BH; Mattes-Ritz A; Guo L; Soiffer RJ; Antin JH; Ritz J
    J Exp Med; 2004 Apr; 199(8):1133-42. PubMed ID: 15096539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human MHC class I transgenic mice deficient for H2 class I expression facilitate identification and characterization of new HLA class I-restricted viral T cell epitopes.
    Cheuk E; D'Souza C; Hu N; Liu Y; Lang H; Chamberlain JW
    J Immunol; 2002 Nov; 169(10):5571-80. PubMed ID: 12421934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy with antibody-targeted HLA class I complexes: results of in vivo tumour cell killing and therapeutic vaccination.
    Savage P; Dyson J; Milrain M; Mathews D; King B; Chan HT; Barber L; Epenetos A; Ogg G; McMichael A; Glennie MJ; French RR
    Tumour Biol; 2007; 28(4):205-11. PubMed ID: 17709989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The DBY gene codes for an HLA-DQ5-restricted human male-specific minor histocompatibility antigen involved in graft-versus-host disease.
    Vogt MH; van den Muijsenberg JW; Goulmy E; Spierings E; Kluck P; Kester MG; van Soest RA; Drijfhout JW; Willemze R; Falkenburg JH
    Blood; 2002 Apr; 99(8):3027-32. PubMed ID: 11929796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MHC class II antigen presentation pathway in murine tumours: tumour evasion from immunosurveillance?
    Walter W; Lingnau K; Schmitt E; Loos M; Maeurer MJ
    Br J Cancer; 2000 Nov; 83(9):1192-201. PubMed ID: 11027433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. H2-O influence on antigen presentation in H2-E-expressing mice.
    Alfonso C; Williams GS; Karlsson L
    Eur J Immunol; 2003 Jul; 33(7):2014-21. PubMed ID: 12884868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of H2-O influence on antigen presentation by B cells.
    Alfonso C; Williams GS; Han JO; Westberg JA; Winqvist O; Karlsson L
    J Immunol; 2003 Sep; 171(5):2331-7. PubMed ID: 12928379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD40-stimulated B lymphocytes pulsed with tumor antigens are effective antigen-presenting cells that can generate specific T cells.
    Lapointe R; Bellemare-Pelletier A; Housseau F; Thibodeau J; Hwu P
    Cancer Res; 2003 Jun; 63(11):2836-43. PubMed ID: 12782589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer associated aberrant protein O-glycosylation can modify antigen processing and immune response.
    Madsen CB; Petersen C; Lavrsen K; Harndahl M; Buus S; Clausen H; Pedersen AE; Wandall HH
    PLoS One; 2012; 7(11):e50139. PubMed ID: 23189185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD4 Donor Lymphocyte Infusion Can Cause Conversion of Chimerism Without GVHD by Inducing Immune Responses Targeting Minor Histocompatibility Antigens in HLA Class II.
    van Balen P; van Bergen CAM; van Luxemburg-Heijs SAP; de Klerk W; van Egmond EHM; Veld SAJ; Halkes CJM; Zwaginga JJ; Griffioen M; Jedema I; Falkenburg JHF
    Front Immunol; 2018; 9():3016. PubMed ID: 30619360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunization with a peptide containing MHC class I and II epitopes derived from the tumor antigen SIM2 induces an effective CD4 and CD8 T-cell response.
    Kissick HT; Sanda MG; Dunn LK; Arredouani MS
    PLoS One; 2014; 9(4):e93231. PubMed ID: 24690990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HLA-DM constrains epitope selection in the human CD4 T cell response to vaccinia virus by favoring the presentation of peptides with longer HLA-DM-mediated half-lives.
    Yin L; Calvo-Calle JM; Dominguez-Amorocho O; Stern LJ
    J Immunol; 2012 Oct; 189(8):3983-94. PubMed ID: 22966084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unexpected reactivities of T cells selected by a single MHC-peptide ligand.
    Singh N; Van Kaer L
    J Immunol; 1999 Oct; 163(7):3583-91. PubMed ID: 10490950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The love and hate relationship of HLA-DM/DO in the selection of immunodominant epitopes.
    Welsh RA; Sadegh-Nasseri S
    Curr Opin Immunol; 2020 Jun; 64():117-123. PubMed ID: 32599219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proper development of long-lived memory CD4 T cells requires HLA-DO function.
    Song N; Welsh RA; Sadegh-Nasseri S
    Front Immunol; 2023; 14():1277609. PubMed ID: 37908352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.